Who
Eric Joseph Daniels
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Plus Therapeutics; Chief Development Officer, Kiora Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 1
- Sells
- 0
- Bought
- $7,570
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 21 Oct 2021
- Last trade
- 20 Apr 2026
- Last filed
- 22 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Apr 2026filed 22 Apr 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1,812929 at $1.95 | filing |
| 1 Apr 2026filed 2 Apr 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1,812929 at $1.95 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,533 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,067 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,067 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,533 at $0.00 | filing |
| 3 Mar 2026filed 6 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $481238 at $2.02 | filing |
| 3 Mar 2026filed 6 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $481238 at $2.02 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,543 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,772 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,710 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,355 at $0.00 | filing |
| 14 Jun 2024filed 14 Jun 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $7,5701,431 at $5.29 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,400 at $0.00 | filing |
News
Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveyKPRX · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Eric Joseph Daniels; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.